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ABSTRACT: Variants in cullin 4B (CUL4B) are a known
cause of syndromic X-linked intellectual disability. Here,
we describe an additional 25 patients from 11 families with
variants in CUL4B. We identified nine different novel
variants in these families and confirmed the pathogenicity
of all nontruncating variants. Neuroimaging data, avail-
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able for 15 patients, showed the presence of cerebral
malformations in ten patients. The cerebral anomalies
comprised malformations of cortical development (MCD),
ventriculomegaly, and diminished white matter volume.
The phenotypic heterogeneity of the cerebral malforma-
tions might result from the involvement of CUL-4B in
various cellular pathways essential for normal brain de-
velopment. Accordingly, we show that CUL-4B interacts
withWDR62, a protein in which variants were previously
identified in patients with microcephaly and a wide range
of MCD. This interaction might contribute to the develop-
ment of cerebral malformations in patients with variants
in CUL4B.
Hum Mutat 36:106–117, 2015. C© 2014 Wiley Periodicals, Inc.
KEYWORDS:CUL4B; WDR62; cortical dysplasia; hydro-
cephalus; intellectual disability; mutation
Introduction
Variants in cullin 4B (CUL4B; MIM #300304) are a known cause
of syndromic X-linked intellectual disability (XLID) [Tarpey et al.,
2007;Zouet al., 2007], includingCabezas syndrome(MIM#300354)
C© 2014 WILEY PERIODICALS, INC.
[Cabezas et al., 2000]. So far, 13 families with 12 uniqueCUL4B vari-
ants have been reported [Wei et al., 1993; Cabezas et al., 2000; Vitale
et al., 2001; Tarpey et al., 2007; Zou et al., 2007; Badura-Stronka
et al., 2010; Isidor et al., 2010; Ravn et al., 2012; Londin et al., 2014].
Tarpey et al. [2007] estimated the frequency ofCUL4B variants lead-
ing to XLID to be around 3% based on a screen of 250 families. The
overlapping phenotype in patients with CUL4B variants consists
of intellectual disability (ID), seizures, tremors, gait abnormalities,
behavioral problems, macrocephaly, short stature, obesity, hypogo-
nadotrophic hypogonadism, and variable dysmorphic features.
CUL4B encodes CUL-4B, a member of the cullin protein fam-
ily [Sarikas et al., 2011]. Cullin proteins form, together with a re-
ally interesting new gene (RING)-finger protein, a cullin–RING
ligase (CRL) complex that has E3 ubiquitin ligase activity [Jack-
son and Xiong, 2009]. E3 ubiquitin ligases are involved in the last
step of protein ubiquitination, which usually results in degradation
of its substrates by the proteasome [Pickart, 2001]. CUL-4B does
not interact with its substrate directly, but through a linker pro-
tein, DNA damage-binding protein 1 (DDB1), which binds to a
substrate-recognition protein [Angers et al., 2006]. Various specific
substrate-recognition proteins are known for the CRL4B through
which CUL-4B is considered to be involved in the regulation of
numerous proteins. Highly predictive of binding to DDB1 is the
presence of a DDB1-binding WD40 (DWD) box [He et al., 2006].
SuchaDWDboxwaspreviously identified in lissencephaly-1protein
(LIS-1) [Higa et al., 2006], variants in which result in lissencephaly
[Lo Nigro et al., 1997]. Furthermore, WD repeat-containing pro-
tein 62 (WDR62), variants inwhich lead tomicrocephaly and awide
range of malformations of cortical development (MCD) [Bilguvar
et al., 2010; Nicholas et al., 2010; Yu et al., 2010; Bhat et al., 2011], is
also predicted to have a DWD box. The potential interaction of LIS-
1 and/or WDR62 with CUL-4B suggests that CUL-4B might also
be involved in regulation of proper brain development. Moreover,
Cul-4b was recently implicated in proliferation and organization of
neuronal cells [Chen et al., 2012; Liu et al., 2012]. Although macro-
cephaly is a frequently observed feature in patients with CUL4B
variants, so far no detailed description of brain abnormalities has
been published.
Here, we provide detailed genotype and phenotype information
of 25 patients from 11 families with variants in CUL4B. We specif-
ically studied the consequences of CUL4B variants on brain devel-
opment. We collected neuroimaging data of a cohort of 15 patients
with pathogenic variants in CUL4B. In addition, we investigated a
possible interaction between CUL-4B and WDR62 or LIS-1.
Patients and Methods
Identification of CUL4B Variants in Patients with XLID
Eight families with variants in CUL4B (NM 003588.3;
NP 003579.3) were identified by massive parallel sequencing in
a cohort of 407 families with XLID at the Department of Hu-
man Molecular Genetics, Max Planck Institute for Molecular Ge-
netics, Berlin, Germany (Supp. Methods). Detailed clinical data
were collected of 20 patients from these eight families and of two
patients from one family with a deletion upstream of exon 2 of
CUL4B (chrX:119,578,701–119,584,448,NCBI36,Hg18) previously
described by Whibley et al. [2010]. This study was approved by the
institutional review board Commissie Mensgebonden Onderzoek
Regio Arnhem-Nijmegen. Written informed consent was obtained
for all patients according to the World Medical Association Decla-
ration of Helsinki.
Identification of CUL4B Variants in Patients with Cortical
Malformations
We studied a cohort of 29 patients with diverse MCD, includ-
ing one affected brother pair from nonconsanguineous parents.
The MCD of these patients consisted of polymicrogyria (PMG) (in
16 patients), the lissencephaly spectrum (in ten patients), or cor-
tical dysplasia (in three patients). In 17 patients, massive parallel
sequencing was performed (Supp. Methods). The other 12 patients
were examined for CUL4B variants by Sanger sequencing.
Review of Neuroimaging Data of Patients with CUL4B
Variants
All neuroradiological data, available of 12 patients from seven of
the XLID families and of the three patients from two families with
MCD, were systematically reevaluated by two independent experts
(N.B.B. and A.J.B.).
Sanger Sequencing
Validation of variants and sequencing of the coding exons of the
CUL4B gene was performed using Sanger sequencing on DNA ex-
tracted from peripheral blood. Primer sequences and conditions for
PCRare available upon request. PCRproductswere sequencedusing
the ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready
Reaction Kit and analyzed with the ABI PRISM 3730 DNA analyzer
(Applied Biosystems, Foster City, CA). DNA of all available family
members was analyzed for the variant found in the index patient to
confirm the segregation of the variant with the disease. Nucleotide
numbering uses +1 as the A of the ATG translation initiation codon
in the reference sequence (NM 003588.3, NP 003579.3), with the
initiation codon as codon 1. All variants identified in this study have
been submitted to http://www.lovd.nl/CUL4B.
RT-PCR Analysis
RNA was isolated from Epstein–Barr Virus transformed lym-
phoblastoid cell lines byusing theNucleoSpinRNAII kit (Macherey-
Nagel,Du¨ren,Germany) according tomanufacturer’s protocols.The
integrity of the RNA was assessed on 1.2% nondenaturing agarose
gel, and the concentration and purity determined by nanodrop
1000 photospectrometer (Thermo Scientific, Waltham, MA). The
OD260/OD230 and OD260/OD280 ratios were in between 1.8 and 2.0.
Five hundred nanograms of total RNA was transcribed into cDNA
by using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Her-
cules, CA) according to manufacturer’s protocol. Primer sequences
and PCR conditions for reverse transcriptase PCR of CUL4B are
available on request. Reverse transcriptase PCR products were as-
sessed by agarose gel analysis and subsequently sequenced using the
ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Re-
action Kit and analyzed with the ABI PRISM 3730 DNA analyzer
(Applied Biosystems).
Plasmid Construction and Transfection
HEK293T cells stably expressing wild-type (WT) or mutant
FLAG-tagged CUL-4B were created as described in the Supp.
Methods.
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Immunoprecipitation
Cellswerewashedwithphosphate-buffered saline (PBS) and lysed
in NP-40 lysis buffer (0.5% Nonidet P-40, 50 mM Tris (pH 7.5),
150 mMNaCl, 10% glycerol and protease inhibitor cocktail) at 4°C
for 5min. Crude lysates were cleared by centrifugation at 17,000× g
at 4°C for 15 min, and supernatants were incubated with FLAG
M2-agarose (Sigma, St. Louis, MO). The immunocomplexes were
washed three times with wash buffer (0.1% Triton X-100, 10%
glycerol in PBS) and then subjected to SDS-PAGE.
Cycloheximide Chase Experiment
Cells were treated with cycloheximide (50 μg/ml) for 0 to 6 hr,
and then lysedwith radioimmunoprecipitation assay buffer (50mM
Tris [pH 8.0], 0.1% SDS, 150 mM NaCl, 1% Nonidet P-40, 0.5%
sodium deoxycholate, and protease inhibitor cocktail) at 4°C for
5 min. Crude lysates were cleared by centrifugation at 17,000 × g
at 4°C for 15 min, and supernatants were subjected to immunoblot
analysis.
Immunofluorescence Staining
U2OS cells grown on glass coverslips were transfected using Fu-
gene 6 transfection reagent (Roche, Indianapolis, IN) according
to manufacturer’s instruction and subsequently prepared for im-
munostaining. In brief, the cells were fixed for 10 min at –20°C
with methanol and then incubated for 1 hr at room temperature
with lab-made anti-FLAG antibody containing 1.0% bovine serum
albumin and 0.5% Triton X-100, and then for 1 hr at room temper-
ature with rhodamine-labeled goat polyclonal antibody to mouse
immunoglobulin (Molecular Probes, Grand Island, NY) at a dilu-
tion of 1:2,000. After washing the cells with PBS containing Triton
X-100, 5μg/ml 4′,6-diamidino-2-phenylindole was added for 1min
at room temperature after which cells were examined with fluores-
cence microscope.
Antibodies
The antibodies used were anti-FLAGM2-HRP antibody (A8592;
Sigma), anti-SGN5 (sc-13157; Santa Cruz, Paso Robles, CA),
anti-tubulin (MS-581-P0; NeoMarkers, Fremont, CA), anti-WD
repeat-containing protein 5 (anti-WDR5) (ab22512, Abcam, Cam-
bridge, England), anti-WDR62 (A301–560A; Bethyl, Montgomery,
TX), anti-LIS1 antibody (AB5413, Millipore, Billerica, MA), anti-
RBX1, and anti-DDB1 (both generated as described previously
[Ohta et al., 1999; Hu et al., 2004]).
Results
Cerebral Abnormalities in Patients with CUL4B Variants
Variants in CUL4B were detected in eight families (families 1–8)
by massive parallel sequencing of 407 families with XLID (2.0% of
the entire cohort). Neuroimaging data were available for 11 patients
from six of these families and for one patient from a previously
reported family with a deletion just upstream of exon 2 (family 9)
[Whibley et al., 2010]. Cerebral abnormalities consisting of MCD,
ventriculomegaly, and a decrease in white matter volume of variable
extent were observed in seven of these 12 patients. We subsequently
screened a group of 29 patients (27 sporadic cases and one af-
fected brother pair) with MCD for variants in CUL4B. This analysis
revealed an additional three patients from two families (families
10–11) with a pathogenic variant in CUL4B.
In total, we identified ten patients with CUL4B variants and vari-
able cerebral abnormalities (Table 1, Fig. 1). The most severe end
of the spectrum consisted of severe ventriculomegaly in combina-
tion with bilateral persylvian PMG or a simplified gyral pattern
with a slightly thickened cortex (family 1, individual IV:3 and fam-
ily 10, individuals II:1 and II:2, respectively; Fig. 1A–E). In family
1, ventriculomegaly was also present in the other two patients for
whom magnetic resonance imaging (MRI) images were not avail-
able. Three of thefivepatientswith severe ventriculomegaly required
shunt placement to reduce the increased intracranial pressure due
to excess cerebrospinal fluid. The intermediate stage, present in two
other unrelated patients, showed a cortical dysplasia of the right
hemisphere parietal (family 4, individual III:1) or bilateral perisyl-
vian PMG (family 11, individual II:2; Fig. 1F and G). At the mild
end of the spectrum, the cerebral anomalies were more subtle. In-
dividual III:1 of family 2 and the two brothers of family 5 (III:1
and III:2) showedmildly diminished white matter volume andmild
ventriculomegaly (Fig. 1H and I). Other brain abnormalities that
were observed consisted of a thin corpus callosum (in three pa-
tients), cerebellar vermis atrophy (in two patients), hyperintensity
of thewhitematter (in twopatients), persistent cavumseptumpellu-
cidum, cavum veli interpositi, geminolytic cysts, and small thalami,
hippocampi, pons, and cerebral peduncles.
Clinical Phenotype of Patients with CUL4B Variants
Detailed clinical information was available of 22 patients from
the nine families from the XLID cohort and of the three patients
from the two families from the MCD cohort. The age of the pa-
tients ranged from two to 45 years. The clinical phenotype of the
patients with theCUL4B variants overlappedwith that of previously
described patients (Table 2 and Supp. clinical reports). ID, which
was usually moderate with a disproportionately severely affected
speech development, was present in all patients. Other neurologi-
cal problems were also frequently noted, such as behavioral prob-
lems (59%), gait abnormalities (48%), tremors (45%), and seizures
(32%). Additional prominent features were genital abnormalities
including hypogonadism (85%), short stature (77%), small hands
(74%), kyphosis (35%), gynecomastia (33%), and macrocephaly
(32%). Frequent facial dysmorphisms consisted of a high forehead
(76%), a prominent lower lip (78%), andmalformed and/or abnor-
mally positioned ears (89%) (Fig. 2). The facial phenotype changed
with age. At a younger age, there was often a depressed nasal bridge
with a bulbous tip (55%), while at an older age the facial appearance
became more coarse, with hyperplastic supraorbital ridges (77%)
and prognathia (68%).On the basis of our and previously published
clinical data, we developed a guideline that can be used to identify
potential patients with CUL4B variants (Supp. Table S1).
CUL4B Variants
TheCUL4B variants identified in this study were spread through-
out the gene and consisted of a missense change, an in-frame dele-
tion of three base pairs, an in-frame duplication of three base pairs,
two splice site variants, and five truncating variants, including a five
base pair deletion (family 4, p.(Ile336Lysfs∗2)) that was reported
previously in an unrelated family [Tarpey et al., 2007] (Fig. 3).
All variants were confirmed by Sanger sequencing and segregated
with the disease in the families, except in family 5, in which one
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Figure 1. Representative MRI and computed tomography (CT) images from patients with CUL4B variants. A and B: Family 10—individual II-1
(2.5 years): MRI T1 axial (A) and sagittal (B) sections show severe ventricular enlargement (colpocephaly), arched and thin corpus callosum, and a
slightly thick and undersulcated cortex (arrows). C and D: Family 10—individual II-2 (6 months, before placement of VP-shunt): MRI T2 axial (C) and
CT scan sagittal (D) sections show severe ventricular enlargement, arched and thin corpus callosum, and a very simplified gyral pattern (arrows).
E: Family 1—individual IV-3 (6 weeks): CT scan axial section shows severe ventricular enlargement and bilateral perisylvian PMG (arrows). F and
G: Family 11—individual II-2 (Day 13): T2 axial section (F) and parasagittal section through left perisylvian area (G) show bilateral perisylvian PMG
(arrows). H and I: Family 2—individual III-1 (2 years): T1 axial (H), and sagittal (I) sections show a mild predominantly posterior ventriculomegaly
and a thin corpus callosum.
intellectually disabled half-brother, who was born from the same
mother, did not carry the c.2493+3A>G variant in CUL4B (Fig. 3B).
All novel variants were assessed for their pathogenicity. Truncat-
ing variants were considered to be pathogenic as described before
[Tarpey et al., 2007]. Two variants, c.2493+3A>G (family 5) and
c.1906+1G>T (family 7), were predicted to influence normal splic-
ing by MaxEntScan [Yeo and Burge, 2004] and NNSPLICE version
0.9 [Reese et al., 1997]. For c.2493+3A>G, the MAXENT score was
reduced from 5.46 to 0.06 and the NNSPLICE donor site prediction
score from 0.57 to zero. For c.1906+1G>T, the MAXENT score was
reduced from 8.60 to 0.10 and the NNSPLICE donor site prediction
score from 0.92 to zero. Both variants were investigated by RT-PCR
analysis on cDNA from the index patient. The variant c.2493+3A>G
abolished the splice donor site of exon 20, leading to the activation
of two cryptic splice donor sites within exon 20, which both re-
sulted in a frameshift and a premature termination codon in exon
21 (Fig. 3C). The variant c.1906+1G>T abolished the splice donor
site of exon 15, which resulted in skipping of exon 15 leading to a
deletion of 37 amino acid residues (p.(Gly599 His635del)) within
the cullin domain (Fig. 3D).
To determine the effect of the single amino acid changes
p.(Leu785del) (family 2), p.(Ala621dup) (family 3), and
p.(Pro50Leu) (family 10) on the function of CUL-4B, we analyzed
the degradation of WDR5, one of the targets of the CRL4B [Naka-
gawa and Xiong, 2011], in HEK293T cells stably expressingWT and
mutant FLAG-tagged CUL-4B. For all three mutants, the WDR5
protein levels were elevated compared to WT (Fig. 4A). There were
no indications that the bindingof themutatedCUL-4B to theRING-
finger RBX1, DDB1, and COP9 signalosome complex subunit 5
(SGN5), three known interactors of CUL-4B [Sarikas et al., 2011],
was significantly affected (Supp. Fig. S1A). Two out of three mutant
CUL-4Bproteins showeddecreasedprotein stability (Fig. 4B),which
might explain the impaired CUL-4B function of these mutants.
The missense change p.(Pro50Leu) did not show decreased protein
stability, but since this variant is close to the nuclear localization sig-
nal (NLS) of CUL4B, we hypothesized that this variant may have an
impact on the subcellular localization of CUL-4B. However, subcel-
lular localization of all three mutants by immunostaining showed a
normal nuclear localization of CUL-4B (Supp. Fig. S1B), suggesting
that thismutant impactsCUL-4B functionby adifferentmechanism
than affecting protein stability or nuclear localization.
Interaction of CUL-4B with LIS-1 and WDR62
Two proteins that are known to cause cerebral malformations,
WDR62 [Bilguvar et al., 2010; Nicholas et al., 2010; Yu et al., 2010]
and LIS-1 [Lo Nigro et al., 1997], contain a DWD box sequence
(Supp. Fig. S2A), which is predictive of binding to DDB1 [He et al.,
2006], an essential component of the CRL4B. Immunoprecipita-
tion (IP) of CUL-4A and CUL-4B in HEK293T cells followed by
immunoblot of precipitates showed that WDR62 interacts with
CUL-4B, but not with CUL-4A (Fig. 4C). Similar IP experiments
investigating a possible interaction of LIS-1 with CUL-4B showed
no LIS-1 in the precipitates, suggesting that LIS-1 does not interact
with CUL-4B (Supp. Fig. S2B).
It was previously shown for WDR5 that DWD proteins can-
not only function as substrate-recognition proteins, but can also
be substrates for degradation by CUL-4B themselves [Nakagawa
and Xiong, 2011]. Therefore, we investigated whether knockdown
of CUL-4B by short-hairpin RNA influenced protein expression
of WDR62 and LIS-1. Protein levels of WDR62 and LIS-1 were
not influenced by knockdown of CUL-4B, whereas WDR5 levels
were influenced by knockdown of CUL-4B, suggesting thatWDR62
and LIS-1 are no direct substrates of CUL-4B themselves (Supp.
Fig. S2C). Normal protein levels of WDR62 and LIS-1 were also
seen for the different mutant FLAG-tagged CUL-4B expressing cells
(Fig. 4A).
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Figure 2. Images of patients with CUL4B variants. Recurrent facial dysmorphisms include high/prominent forehead, malformed, and abnormally
positioned ears, hyperplastic supraorbital ridges/deep-set eyeswith narrowpalpebral fissures, lownasal bridgewith a rounded nasal tip, prominent
lower lip, andprognathia. Extremities showsmall hands/feetwith brachydactyly, clinodactyly, syndactyly 2–3of toes, and sandal gap. For description
of dysmorphisms, see Table 2.
Discussion
In this article, we describe detailed neuroradiological data of
15 male patients and overall clinical data of 25 patients derived
from11 familieswithpathogenic variants affectingCUL4B.Ourdata
show for the first time a firm association between CUL4B variants
and cerebral malformations. Detailed assessment of neuroimaging
data showed that cerebral malformations comprising MCD, ven-
triculomegaly, and diminished white matter volume were present
in ten of 15 patients investigated. The CUL4B-associated cerebral
malformationswere of variable severity, the severest form consisting
ofmassive ventriculomegaly in combination withMCD. Known ge-
netic causes of X-linked hydrocephalus (L1CAM and AP1S2) were
excluded in these families. In the remaining patients, the sever-
ity of the cerebral malformations ranged from bilateral MCD to
more subtle diminished white matter volume and ventricular en-
largement. We did not observe a correlation between the type or
position of the variant and the severity of the cerebral abnormal-
ities. However, within the three families for whom neuroimaging
data were available of multiple affected individuals (families 1, 5,
and 10), the cerebral abnormalities were strikingly similar among
the different family members, which suggests that there might be a
variant-specific effect of the respective CUL4B variants on cerebral
development.
Cerebral malformations have not been reported to date as a fea-
ture associated withCUL4B variants, except for one individual from
family 43 who was reported to have a porencephalic cyst in the
original description of this condition [Tarpey et al., 2007]. How-
ever, detailed and systematic neuroimaging analysis of patients with
CUL4B variants has not been performed until now. Accordingly,
MRI analysis of additional affected family members of family 43 has
now also shown the presence of abnormalities of the lateral ventri-
cles, corpus callosum, and heterotopic gray matter (F.L. Raymond,
personal communication), further supporting our finding that cere-
bral malformations are a significant feature in patients with CUL4B
variants.
Our data suggest that CUL-4B plays an important role in brain
development. This is supported by the observation of abnormal
neuronal organization in thehippocampus inCul-4bknockoutmice
[Chen et al., 2012]. Furthermore, Cul-4b was shown to be essential
for proliferation of neural progenitor cells in rodents as knockdown
of Cul-4b accumulated these cells in the G2/M phase of the cell cycle
[Liu et al., 2012]. A general involvement of the cullin family in brain
development is further supported by mice with a knockdown of
HUMANMUTATION, Vol. 36, No. 1, 106–117, 2015 113
Figure 3. Overview of CUL4B variants identified in this study. A: Schematic overview of the CUL4B gene including the 22 exons and known
domains. The positions of all previously described variants [Tarpey et al., 2007; Zou et al., 2007; Badura-Stronka et al., 2010; Isidor et al., 2010;
Whibley et al., 2010; Ravn et al., 2012; Londin et al., 2014] and novel variants are depicted. Recurrent variants are depicted in bold; novel variants
from this study are marked with a hash (#). Nuclear localization signal (NLS) is shown in red, cullin domain in blue, and neddylation domain
(Nedd8) in green. B: Pedigrees of families with CUL4B variant and results from segregation studies. Mutant alleles are represented by a plus (+)
and WT alleles by a minus (–). Arrows indicate probands. Below each pedigree, Sanger sequencing chromatograms of the proband (top) and a
control (bottom) are depicted. C: RT-PCR analysis of CUL4B splice site variant of family 5. Alternative splicing occurs between exon 20 and 21. Two
alternative splice donor sites within exon 20 are used, which result in premature termination codons at amino acid position 806 (splice variant 1;
SV1) and 811 (SV2), respectively. P, patient; C, control. D: RT-PCR analysis of CUL4B splice site variant of family 7. The variant leads to skipping of
exon 15, which results in a 111 base pair shorter transcript as confirmed by agarose gel electrophoresis and subsequent Sanger sequencing. L,
DNA size ladder; P, patient; C, control.
cullin 5, which also show aberrant neuronal migration [Feng et al.,
2007].
The identification of an in vivo interaction between CUL-4B and
WDR62 provides a possible mechanism for the development of
cerebral malformations in patients with aCUL4B variant. Homozy-
gous variants in WDR62 result in microcephaly and a wide range
of MCD [Bilguvar et al., 2010; Nicholas et al., 2010; Yu et al., 2010;
Bhat et al., 2011], including cortical thickening, pachygyria, simpli-
fied gyral pattern, PMG, heterotopias, and schizencephaly [Bilguvar
et al., 2010; Nicholas et al., 2010; Yu et al., 2010; Bhat et al., 2011].
MCDare also present in five of our patients.However, while variants
inWDR62 lead to severe and profound microcephaly, patients with
CUL4B variants usually have macrocephaly with ventriculomegaly
and diminished white matter volume, although microcephaly has
been reported in two families [Wei et al., 1993; Vitale et al., 2001;
Zou et al., 2007; Londin et al., 2014]. The interaction with WDR62
is specific for CUL-4B, as IPs with an anti-CUL-4A antibody did not
result in coprecipitation of WDR62. The main difference between
these paralogues is that CUL-4B has an extendedN-terminus, which
contains a nuclear localization signal [Zou et al., 2009; Nakagawa
and Xiong, 2011]. The subcellular localization of WDR62 has been
reported to be cell cycle and tissue dependent [Bilguvar et al., 2010;
Nicholas et al., 2010; Yu et al., 2010; Bhat et al., 2011]. In neuronal
cells, WDR62 has been shown to localize predominantly to the nu-
cleus [Bilguvar et al., 2010; Nicholas et al., 2010], suggesting that
WDR62 and CUL-4B interact in the nucleus and form a complex
necessary for proper cerebral development. We were not able to de-
tect an interaction between LIS-1 and CUL-4B. However, LIS-1 has
previously been shown to interact with DDB1 [Higa et al., 2006]. As
LIS-1mainly localizes to the centrosome and the perinuclear region,
but not to the nucleus [Tanaka et al., 2004], it could well be that
LIS-1 binds to DDB1 in the cytoplasm, but that it does not interact
with nuclear CUL-4B. However, we cannot exclude that during cell
division CUL-4B is able to interact with LIS-1.
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Figure 4. Effect of the novel amino acid altering variants p.(Leu785del), p.(Ala621dup), and p.(Pro50Leu) on the function of CUL-4B (A and B) and
interaction of normal CUL-4B with WDR62 (C). A: Western blot showing the WDR5, LIS-1, and WDR62 protein levels in HEK293T cells expressing
WT, p.(Pro50Leu), p.(Ala621dup), and p.(Leu785del) FLAG-tagged CUL-4B (left panel). Levels of WDR5 in all three mutants are increased compared
to WDR5 levels in WT. Levels of LIS-1 and WDR62 are normal. Tubulin is shown as control. B: Cycloheximide chase experiments in HEK293T cells
show that novel amino acid altering variants p.(Ala621dup) and p.(Leu785del) result in an unstable protein as compared to WT, whereas CUL-4B
with the p.(Pro50Leu) change is not degraded faster. Tubulin is shown as a control. C: IP experiments in HEK293T cells with antibodies against
CUL-4A (upper panel) and CUL-4B (lower panel) with subsequent immunoblot of the precipitates show thatWDR62 binds to CUL-4B, but not CUL-4A.
DDB1 is shown as a control.
The development of cerebral malformations in patients with
CUL4B variants might also result from the disturbance of other
pathways, as currently more than 20 proteins are known to be sub-
strates of CRL4 ubiquitin ligase complex [Kerzendorfer et al., 2011;
Li et al., 2011]. CUL-4B is hypothesized to regulate the mTORC1
signaling pathway, as knockdown of CUL-4B results in decreased
phosphorylation of ribosomal protein S6 kinase beta-1 and eu-
karyotic translation initiation factor 4E-binding protein 1 [Ghosh
et al., 2008; Kerzendorfer et al., 2011]. This downregulation is likely
mediated by increased stability of DNA damage inducible tran-
script 4 protein and tuberin, two targets of the CRL4 ubiquitin
ligase complex [Hu et al., 2008; Katiyar et al., 2009; Wang et al.,
2013]. The mTOR pathway was recently linked to megalencephaly–
PMG–polydactyly–hydrocephalus (MPPH) syndrome, which also
has the combination of the phenotypic features of MCD and ven-
triculomegaly. Activating de novo variants in AKT3, PIK3R2, and
PIK3CA, three core components of this pathway, were identified
in patients with this phenotype [Riviere et al., 2012]. However,
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knockdown of CUL-4B is currently only associated with downreg-
ulation of mTOR signaling, whereas the variants seen in MPPH
syndrome were shown to lead to upregulation of this signaling
pathway.
Variants in CUL4B might also affect chromatin remodeling.
Knockdown of CUL-4B results in increased WDR5 levels, a core
member of the SET1/MLL family of histonemethyltransferase com-
plexes [Dou et al., 2006; Trievel and Shilatifard, 2009]. An increase
in WDR5 was previously shown to lead to increased expression
of several neuronal genes through increased H3K4me3 levels at
their promoters [Nakagawa and Xiong, 2011]. Moreover, CUL-4B
can also influence chromatin remodeling through monoubiquiti-
nation of histone H2A lysine 119 [Hu et al., 2012; Yang et al., 2013].
Impaired chromatin remodeling, more specifically also increased
H3K4 methylation, is a common mechanism underlying ID [van
Bokhoven, 2011], for example, in patients with KDM5C variants
[Iwase et al., 2007; Tahiliani et al., 2007], and is also implicated in
cerebral development [Yang et al., 2012].
In conclusion, we show that CUL4B variants are associated with
a wide range of cerebral malformations such as MCD, ventricu-
lomegaly, and diminished white matter volume. The phenotypic
heterogeneity might result from the involvement of CUL-4B in var-
ious cellular pathways essential for normal brain development. Ac-
cordingly, we show that CUL-4B interacts with WDR62, a protein
in which variants were previously identified in patients with micro-
cephaly and a wide range ofMCD, providing a potential mechanism
for the development of these brain abnormalities in patients with
CUL4B variants.
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